Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

por Larkin, James, Del Vecchio, Michele, Mandalá, Mario, Gogas, Helen, Arance Fernandez, Ana M., Dalle, Stéphane, Cowey, Charles Lance, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Marquez-Rodas, Ivan, Butler, Marcus O., Di Giacomo, Anna Maria, Middleton, Mark R., Lutzky, Jose, de la Cruz-Merino, Luis, Arenberger, Petr, Atkinson, Victoria, Hill, Andrew G., Fecher, Leslie A., Millward, Michael, Nathan, Paul D., Khushalani, Nikhil I., Queirolo, Paola, Ritchings, Corey, Lobo, Maurice, Askelson, Margarita, Tang, Hao, Dolfi, Sonia, Ascierto, Paolo A., Weber, Jeffrey
Publicado 2023